Finally, a NK cell line engineered to express a chimeric receptor encompassing the extracellular domain of transforming growth factor beta receptor 2 (TGFBR2) fused to the intracellular domain of NKG2D has recently been shown to mediate superior therapeutic efficacy in preclinical HCC models, reflecting not only improved cytotoxic responses (which could further be ameliorated by TGFB1, at least in vitro), but also (1) enhanced recruitment to the solid TME, and (2) suppressed TREG cell differentiation [184]. Here, TGFBR2 is linked to hepatocellular carcinoma.